BRPI0813455A2 - Derivado de 17beta-ciano-18a-homo-19-nor-androst-4-eno, seu uso e medicamentos contendo este derivado. - Google Patents

Derivado de 17beta-ciano-18a-homo-19-nor-androst-4-eno, seu uso e medicamentos contendo este derivado.

Info

Publication number
BRPI0813455A2
BRPI0813455A2 BRPI0813455-3A2A BRPI0813455A BRPI0813455A2 BR PI0813455 A2 BRPI0813455 A2 BR PI0813455A2 BR PI0813455 A BRPI0813455 A BR PI0813455A BR PI0813455 A2 BRPI0813455 A2 BR PI0813455A2
Authority
BR
Brazil
Prior art keywords
derivative
17beta
androst
homo
cyan
Prior art date
Application number
BRPI0813455-3A2A
Other languages
English (en)
Inventor
Joachim Kuhnke
Jan Huebner
Rolf Bohlmann
Thomas Frenzel
Ulrich Klar
Frederik Menges
Sven Ring
Steffen Borden
Katja Prelle
Hans-Peter Muhn
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of BRPI0813455A2 publication Critical patent/BRPI0813455A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/007—3 membered carbocyclic rings in position 6-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0813455-3A2A 2007-06-12 2008-06-04 Derivado de 17beta-ciano-18a-homo-19-nor-androst-4-eno, seu uso e medicamentos contendo este derivado. BRPI0813455A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007027636A DE102007027636A1 (de) 2007-06-12 2007-06-12 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
PCT/EP2008/004428 WO2008151745A1 (de) 2007-06-12 2008-06-04 17beta-cyano-18a-homo-19-nor-androst-4-en-derivat, dessen verwendung und das derivat enthaltende arzneimittel

Publications (1)

Publication Number Publication Date
BRPI0813455A2 true BRPI0813455A2 (pt) 2014-12-23

Family

ID=38858372

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813455-3A2A BRPI0813455A2 (pt) 2007-06-12 2008-06-04 Derivado de 17beta-ciano-18a-homo-19-nor-androst-4-eno, seu uso e medicamentos contendo este derivado.

Country Status (21)

Country Link
US (1) US20090048218A1 (pt)
EP (1) EP2178899B1 (pt)
JP (1) JP2010529152A (pt)
KR (1) KR20100017780A (pt)
CN (1) CN101679477A (pt)
AR (1) AR066970A1 (pt)
AU (1) AU2008261277A1 (pt)
BR (1) BRPI0813455A2 (pt)
CA (1) CA2689563A1 (pt)
CL (1) CL2008001721A1 (pt)
DE (1) DE102007027636A1 (pt)
ES (1) ES2397879T3 (pt)
IL (1) IL202300A0 (pt)
MX (1) MX2009013626A (pt)
PA (1) PA8784201A1 (pt)
PE (1) PE20090312A1 (pt)
RU (1) RU2010100334A (pt)
TW (1) TW200906846A (pt)
UY (1) UY31145A1 (pt)
WO (1) WO2008151745A1 (pt)
ZA (1) ZA201000185B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010066354A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft VERWENDUNG VON 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
US9388210B2 (en) 2011-02-25 2016-07-12 Washington University Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
CN108976272B (zh) 2011-10-14 2021-05-25 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
ES2680582T3 (es) 2012-12-18 2018-09-10 Washington University Esteroides 19-alcoxi-17-sustituidos neuroactivos, profármacos de los mismos y métodos de tratamiento con los mismos
US9512170B2 (en) 2013-03-01 2016-12-06 Washington University Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
US9365502B2 (en) 2013-03-11 2016-06-14 Washington University Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors
US9562026B2 (en) 2013-03-14 2017-02-07 Washington University Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
HUE051403T2 (hu) 2013-04-17 2021-03-01 Sage Therapeutics Inc Neuroaktív 19-nor-szteroidok kezelési eljárásokhoz
KR20230172622A (ko) 2013-04-17 2023-12-22 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
PT3021852T (pt) * 2013-07-19 2021-04-21 Sage Therapeutics Inc Esteroides neuroativos, composições e utilizações das mesmas
CA2921512A1 (en) 2013-08-23 2015-02-26 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
HUE051488T2 (hu) 2014-10-16 2021-03-01 Sage Therapeutics Inc Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére
US10577390B2 (en) 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
EP3719029A1 (en) 2014-11-27 2020-10-07 Sage Therapeutics, Inc. Compositions for inducing sedation
DK3250210T3 (da) 2015-01-26 2021-03-08 Sage Therapeutics Inc Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
US10329320B2 (en) 2015-02-20 2019-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
RU2019103590A (ru) 2016-07-11 2021-02-11 Сейдж Терапьютикс, Инк. С17-, с20- и с21-замещенные нейроактивные стероиды и способы их применения
JP2022534424A (ja) 2019-05-31 2022-07-29 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド及びその組成物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3043833A (en) * 1961-07-14 1962-07-10 Ormonoterapia Richter Spa 17-cyanohydrin of 19-nor androstenedione and 3-derivatives thereof
DE1183500B (de) 1962-10-12 1964-12-17 Schering Ag Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe
US3579509A (en) * 1965-06-21 1971-05-18 Smith Kline French Lab Process and 6-beta-substituted ethyl intermediates for preparing 6,6-ethylene-3-keto-delta**4 steroids
GB1089945A (en) * 1965-09-23 1967-11-08 British Drug Houses Ltd Steroidal-6-spirocyclopropyl-4-en-3-ones
IL32699A (en) * 1968-07-30 1973-06-29 American Home Prod 6-substituted-13-polycarbonalkyl-18,19 dinorpregn-4-en-3-ones,their preparation and pharmaceutical compositions containing them
FR2081561B1 (pt) * 1970-03-03 1973-04-06 Roussel Uclaf
US3705179A (en) 1971-03-15 1972-12-05 American Home Prod Antiandrogenic steroids
FR2139708B1 (pt) * 1971-06-01 1974-08-23 Roussel Uclaf
US3994937A (en) * 1972-02-11 1976-11-30 Schering Aktiengesellschaft 15α,16α-Methylene-4-estren-17β-ols
BE795241A (fr) 1972-02-11 1973-08-09 Schering Ag 15alpha, 16alpha-methylene-4-oestren-17beta-ols-methylenz-4-oestren-17beta-ols et leur procede de preparation
NL7701384A (nl) 1977-02-10 1978-08-14 Akzo Nv Werkwijze voor het bereiden van nieuwe steroiden van de oestraanreeks.
DE2922500A1 (de) 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
US4252800A (en) * 1979-10-05 1981-02-24 United States Of America 7α-methylnorethindrone enanthate and its use in long term suppression of fertility in female mammals
US4544554A (en) * 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
DE3402329A1 (de) 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
EP0785211A1 (en) * 1996-01-22 1997-07-23 Laboratoire Theramex New substituted 19-nor-pregnane derivatives
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
DE102004063864A1 (de) 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
KR20100017780A (ko) 2010-02-16
RU2010100334A (ru) 2011-07-20
AR066970A1 (es) 2009-09-23
ES2397879T3 (es) 2013-03-12
DE102007027636A1 (de) 2008-12-18
WO2008151745A1 (de) 2008-12-18
EP2178899B1 (de) 2012-10-24
IL202300A0 (en) 2010-06-30
PA8784201A1 (es) 2009-01-23
TW200906846A (en) 2009-02-16
CA2689563A1 (en) 2008-12-18
ZA201000185B (en) 2011-03-30
EP2178899A1 (de) 2010-04-28
AU2008261277A1 (en) 2008-12-18
CN101679477A (zh) 2010-03-24
PE20090312A1 (es) 2009-04-09
CL2008001721A1 (es) 2008-12-19
JP2010529152A (ja) 2010-08-26
UY31145A1 (es) 2009-01-30
MX2009013626A (es) 2010-01-20
US20090048218A1 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
BRPI0813455A2 (pt) Derivado de 17beta-ciano-18a-homo-19-nor-androst-4-eno, seu uso e medicamentos contendo este derivado.
BRPI0821276A2 (pt) Produto, e, uso do produto
BRPI0814267A2 (pt) Agentes citotóxicos compreendendo novos derivados de tomaicmicina e o seu uso terapêutico.
BRPI0910503A2 (pt) compostos, composições farmacêuticas e respectivos usos.
BRPI0815773A2 (pt) composto, e, medicamento.
BRPI0815190A2 (pt) Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo
BRPI0718182A2 (pt) Oligorribonucleotídeos e seus usos.
BRPI0808098A2 (pt) 4-aril-1,4-di-hidro-1,6-naftiridinamidas substituídas e seu uso
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
BRPI0915897A2 (pt) compostos derivados triazóis, composições farmacêuticas e combinações dos mesmos e seus usos
BRPI1010621A2 (pt) derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso
EP2157093A4 (en) HETEROCYCLIC PYRROLO-NITROGEN-DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL USE
BRPI0922435A2 (pt) "composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso."
IL206808A (en) Indolyl-pyridone history, their pharmaceutical preparations and their uses
BRPI0718192A2 (pt) Corantes dispersos, sua preparação e seu uso.
BRPI0719398A2 (pt) Composição farmacêutica.
BRPI0810706A2 (pt) Produtos rotacionalmente moldados e moldes.
BRPI0915552A2 (pt) derivados de ciclosporina, seu uso e sua composição farmacêutica
BRPI0810654A2 (pt) Tiadiazoliloxifenilamidinas e o seu uso como fungicidas.
BRPI0807078A2 (pt) Composto, e, formulação farmacêutica
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
BRPI0907228A2 (pt) Compostos de tienopiridazina, suas preparações, composições farmacêuticas e usos
BRPI0813587A2 (pt) Composto, uso do mesmo, e, composição farmacêutica
BRPI0911772A2 (pt) composto, composição farmacêutica, e, uso do composto.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]